|
Measuring financial toxicity of cancer in the Italian health care system: Initial results of the patient reported outcome for fighting financial toxicity of cancer project (proFFiT). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Janssen; Mediolanum Farmaceutici; Merck Sharp & Dohme; Pfizer; Takeda |
Consulting or Advisory Role - AstraZeneca; Janssen; Mediolanum Farmaceutici; Merck Sharp & Dohme; Pfizer; Takeda |
Research Funding - Tesaro (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Incyte; Orsenix |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Honoraria - Bristol-Myers Squibb; Italfarmaco |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; AstraZeneca; Biogen; Boehringer Ingelheim; Celgene; Gilead Sciences; GlaxoSmithKline; Ipsen; Janssen-Cilag; Sanofi; Takeda |
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sandoz (Inst); Sanofi (Inst); Takeda (Inst) |
|
|
Honoraria - Baxter; Merck Sharp & Dohme; Novartis; Sanofi; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Bayer; Bayer; Bayer; Celgene; Incyte; Janssen-Cilag; Pierre Fabre; Sandoz |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Incyte (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bayer |